Home Featured Page 146

Featured

Latest

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

First Patient Dosed in Small Pharma’s Drug Interaction Study

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Revive Therapeutics Ltd. Expands Life Offering to Quebec

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani,...

Psychedelics Weekly – Proposition 122 in Action, The Economics of Psychedelics,...

FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE...

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert...

MIND CURE ENTERS INTO BINDING LETTER OF INTENT WITH LNG ENERGY...

Psyence Group Announces Closing of Second Tranche of Private Placement and...

EDITOR PICKS

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

First Patient Dosed in Small Pharma’s Drug Interaction Study

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Revive Therapeutics Ltd. Expands Life Offering to Quebec

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani,...

Psychedelics Weekly – Proposition 122 in Action, The Economics of Psychedelics,...

FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE...

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert...

MIND CURE ENTERS INTO BINDING LETTER OF INTENT WITH LNG ENERGY...

Psyence Group Announces Closing of Second Tranche of Private Placement and...

EDITOR PICKS

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY